Cargando…
Luxeptinib interferes with LYN-mediated activation of SYK and modulates BCR signaling in lymphoma
Luxeptinib (LUX) is a novel oral kinase inhibitor that inhibits FLT3 and also interferes with signaling from the BCR and cell surface TLRs, as well as activation of the NLRP3 inflammasome. Ongoing clinical trials are testing its activity in patients with lymphoma and AML. This study sought to refine...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9994718/ https://www.ncbi.nlm.nih.gov/pubmed/36888611 http://dx.doi.org/10.1371/journal.pone.0277003 |